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A 36 kDa fibronectin-binding protein was identified from electrophoretically separated proteins of the de- 
oxycholate-soluble fraction of cultured fibroblasts by blotting with fibronectin and using paly- or monoclo- 
nal antibodies and immunoperoxidase staining to detect the bound fibronectin. The 36 kDa protein was 
purified by preparative electrophoresis and used to raise specific antibodies. Solid-phase 36 kDa protein 
bound plasma nd fibroblast fibronectins equally well. The 36 kDa protein is an amphipathic protein with 
~15.9. It is monomeric with a tendency to dime&e and appears to be distinct from the cell surface fibronec- 
tin receptors which interact with the Arg-Gly-Asp recognition site in the fibronectin molecule. 
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1. INTRODUCTION 
Fibronectin is a high-molecular-mass glycopro- 
tein composed of two similar non-identical 
subunits of 240 kDa. A characteristic feature of 
fibronectin is its wide distribution; it is found in 
soluble form in plasma and other body fluids and 
in insoluble form in tissues and the pericellular 
matrix of cultured cells [ 11. Fibronectin is also well 
known for its many interactions, including those 
with fibrin [2], collagen [3], heparan sulfate pro- 
teoglycan [4] and cell surfaces [5]. It can mediate 
the interaction between cells and extracellular 
matrices. The binding sites for these and many 
other interactions have been located to the dif- 
ferent domains of the fibronectin molecule; the 
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best characterized is the Arg-Gly-Asp (RGD) cell 
recognition sequence [6] in the COOH-terminal 
half within one of the ‘type III’ internal repeats in 
fibronectin. Derivatives of this peptide inhibit the 
adhesion of cells to fibronectin and, if used as an 
insoluble substrate, can simulate the action of the 
whole molecule. 
In human osteosarcoma cells [7], several 
fibroblasts [8-l 11, and murine erythroleukemia 
cells [12] glycoproteins composed of two different 
120-160 kDa subunits interact specifically with 
fibronectin and have been proposed to represent 
fibronectin receptors on the cell surface. In human 
platelets the membrane glycoprotein IIb/IIIa 
(subunits of 142 and 95 kDa) interacts specifically 
with fibronectin [ 13,141. All these interactions are 
inhibited by the RGD cell recognition peptides. 
This sequence may not, however, be the only 
region in the fibronectin molecule that binds to cell 
surfaces; the two heparin-binding domains in the 
NHz- and COOH-terminal regions, respectively, 
possibly carry a similar function. Interaction of 
fibronectin with plasma membrane heparin sulfate 
proteoglycan may be involved in cell spreading and 
cytoskeletal stabilization [15]. We now report the 
isolation of a 36 kDa fibronectin-binding protein 
present in normal human fibroblasts. This protein 
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appears to be distinct from the previously iden- 
tified fibronectin-binding proteins. 
2. MATERIALS AND METHODS 
2.1. Cell cultures, fibronectins and synthetic 
peptide 
Fibronectins were purified from human plasma 
and serum-free medium of cultured human em- 
bryonic fibroblasts using gelatin- and arginine- 
Sepharose, as described [161. In SDS-PAGE under 
reducing conditions purified fibronectins (5 pg), 
gave single bands at 250 kDa. The human fibrosar- 
coma cell line HT-1080 was from the American 
Type Culture Collection (CCL 121; Rockville, 
MD). The synthetic peptide GRGDSP was pro- 
vided by Dr M.-L. Huhtala (Labsystems, Helsinki) 
and was used at 1 mg/ml. 
2.2. SDS-PAGE and blotting experiments 
SDS-PAGE was performed on 5-16% 
acrylamide slab gels according to Laemmli [19]. 
Immunoblotting of proteins was performed using 
immunoperoxidase staining [20] and primary an- 
tibodies as follows: polyclonal anti-fibronectin 
[ 161 at 1: 1000, peroxidase-labeled anti-fibronectin 
at 1 :400, monoclonal f-33 [21] and f-42 [18] anti- 
fibronectin IgGi at lOpg/ml, and polyclonal 
anti-36 kDa protein at 1 : 250. Proteins transferred 
to nitrocellulose filters were incubated for 16 h 
with purified human plasma fibronectin 
(50 pg/ml) in Tween-containing buffer. The filters 
were then washed and immunoblotted. 
If, instead of blotting with native fibronectin, 
‘251-fibronectin or biotinylated fibronectin com- 
bined with peroxidase-avidin was used, a great 
variety of ‘fibronectin-binding’ proteins were seen. 
2.3. Binding experitnen ts
Proteins were immobilized onto polystyrene 
microtiter wells from 4pg/ml (fibronectin or 
albumin) or 400 ng/ml (36 kDa protein) using 
previously described conditions [21,22]. The 
binding to immobilized protein was studied by 
adding a volume of 75 ~11 of different concentra- 
tions of purified protein. Tween (0.02%) was in- 
cluded to prevent nonspecific binding and to 
minimize hydrophobic interactions. The antibody- 
binding activity of solid-phase-bound ligand pro- 
tein was assayed using diluted antibodies 
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(polyclonal anti-fibronectin, 1: 1000; polyclonal 
anti-36 kDa protein, 1 :250; monoclonal f-33 anti- 
fibronectin IgGi, 10 pug/ml) in EIA [21,22]. In all 
experiments, either the soluble or solid-phase pro- 
teins were replaced, as a control, with bovine 
serum albumin or buffer control. When the 
specific antibodies were omitted or replaced with 
the respective preimmune rabbit sera or a 10 pg/ml 
concentration of the anti-trinitrophenyl 
monoclonal antibody [22] no reaction occurred. 
2.4. Isolation of the 36 kDa protein and 
immunization 
Confluent cultures of fibroblasts were rinsed 
twice with ice-cold PBS, and 1 ml of 10 mM Tris- 
HCl (pH 8.0) buffer containing 0.5% (w/v) DOC 
and 1 mM phenylmethylsulfonyl fluoride was 
added per 175 cm2 culture flask tilted gently for 
10 min at + 0°C. The DOC-soluble material was 
collected and clarified by low-speed centrifugation 
in the cold. 
Preparative SDS-PAGE under nonreducing con- 
ditions was used to prepare the antigen for im- 
munization. After SDS-PAGE the proteins were 
transferred electrophoretically onto a nitro- 
cellulose sheet. A track was cut off to locate the 
36 kDa protein using blotting with fibronectin. A 
slice of the sheet containing the 36 kDa protein 
was dissolved in dimethyl sulfoxide and used to im- 
munize rabbits. IgG of the anti-36 kDa protein 
rabbit serum was isolated by conventional 
methods. 
For the binding experiments the 36 kDa protein 
was purified by a modification of the above pro- 
cedure. 14C-labeled molecular mass marker pro- 
teins (Amersham International) were included in 
the sample. A wet preparative SDS-PAGE slab gel 
was dried on a cellophane dialysis membrane 
(LKB, Bromma, Sweden), autoradiographed to 
locate the proteins and the relevant area cut out 
and dissolved in 10 mM NH4HCO3 containing 
0.01% SDS. Electroelution was carried out using a 
model 1750 electrophoretic sample concentrator 
(ISCO, Lincoln, NE) at 1 W (7 mA) for 3 h at 
4°C. 
2.5. Two-dimensional electrophoresis 
The procedure described by Pollard [23], involv- 
ing isoelectric focusing in the first dimension and 
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SDS-PAGE (8% polyacrylamide) in 
was followed using LKB ampholines 
3. RESULTS AND DISCUSSION 
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the second, 
(pH 6-8.5). 
Normal human fibroblasts can be expected to 
contain not only the putative plasma membrane 
receptors but also fibronectin-binding proteins in 
the extracellular matrix in which fibronectin is a 
major component. To separate these two classes of 
molecules, we used a modification of the deox- 
ycholate procedure [24] developed to isolate the 
matrix of cultured fibroblasts. 
The proteins were separated by SDS-PAGE 
under non-reducing conditions and transferred to 
nitrocellulose filter, blotted with purified un- 
labeled human plasma fibronectin and the bound 
fibronectin was detected using immunoperoxidase 
staining. If whole cell layers or matrix material 
(fig.lA,B) were studied a number of fibronectin- 
binding proteins were detected: major bands at 480 
(comigrating with matrix fibronectin), 160, 140, 
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Fig. I. SDS-PAGE of human fibroblast proteins. (A) 
Protein staining: 1, total proteins; 2, isolated matrix; 3, 
DOC-soluble material. (B) Fibronectin blotting using 
polyclonal antibodies: 1, isolated matrix; 2, DOC- 
soluble material. (C) Fibronectin blotting of DOC- 
soluble material: 1, peroxidase-labeled polyclonal 
antibodies; 2, F-33 monoclonal antibodies; 3, F-42 
monoclonal antibodies; 4, control without fibronectin. 
The two dots indicate the positions of 160 and 140 kDa, 
respectively, and the asterisk 36 kDa. Molecular masses 
of standards are indicated on the left. 
Fig.2. (A) Protein staining of SDS-PAGE: 1, starting 
material (DOC-soluble fraction); 2, 36 kDa protein 
purified by preparative SDS-PAGE. (B) Fibronectin 
blotting: 1, starting material; 2, purified 36 kDa protein. 
Immunoblotting with anti-36 kDa protein of total 
proteins from fibroblasts (3) and from HT-1080 sarcoma 
cells (4), and from fibroblasts with anti-36 kDa protein 
IgG (5) and with preimmune IgG (6). 
90, 47 and 36 kDa. In contrast, only a few 
fibronectin-binding proteins were seen (fig.lB, 
lane 2) in the DOC-soluble fraction. These 
migrated at 160, 140, 47 and 36 kDa. As shown in 
fig.lC the bands at 160, 140 and 36 kDa could be 
detected both directly with peroxidase-conjugated 
polyclonal anti-fibronectin and with two 
monoclonal anti-fibronectins followed by anti- 
mouse IgG peroxidase. In different experiments 
the 36 kDa protein was always present while the 
others were sometimes weakly stained or absent. 
The DOC-solubilized fraction of fibroblasts was 
used to develop a purification procedure for the 
36 kDa protein. The two-phase TX-114 detergent 
separation system [25] was used to define whether 
this protein is hydrophobic or hydrophilic. The 
protein was found in both phases. Gel 
chromatography on Fractogel in the presence of 
detergent gave several broad peaks and ir- 
reproducible results ( ‘2sI-labeled 36 kDa protein 
used as marker). In hydrophobic interaction 
chromatography the protein was not recovered in 
383 
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Fig.3. Binding of different concentrations of fibronectin 
to purified 36 kDa protein immobilized on polystyrene. 
Bound fibronectin was detected using EIA. (A) Plasma 
fibronectin and four batches of 36 kDa protein. (B) 
Cellular fibronectin and purified 36 kDa protein. 
the eluants while both the 160 and 140 kDa 
fibronectin-binding proteins bound to octyl- and 
phenyl-Sepharose CL4B. We intended then to use 
reverse-phase HPLC but the protein lost its 
fibronectin-binding capacity in acetonitrile. Thus, 
preparative SDS-PAGE turned out to be the only 
method applicable (fig.2A). Serum of a rabbit im- 
munized with purified 36 kDa protein reacted 
specifically with it in immunoblotting of cell ex- 
tracts (fig.2B). It also reacted with polystyrene 
wells coated with 36 kDa protein, as judged by 
EIA. 
The purified 36 kDa protein was immobilized 
onto polystyrene microtiter wells to study binding. 
As shown in fig.3A, these wells bound fibronectin 
in a dose-dependent manner. The detection limit 
for fibronectin varied between 40 and 400 ng/ml 
for the different 36 kDa protein preparations. 
Coating of the wells with as little as 4 ng/ml of the 
36 kDa protein produced wells able to bind 
fibronectin specifically as detected in EIA. Wells 
coated with 4pg/ml of fibronectin but not un- 
coated wells or those coated with albumin bound 
the 36 kDa protein, as detected using anti-36 kDa 
protein in EIA. The detection limit was 30 ng/ml 
of 36 kDa protein. Cellular fibronectin, purified 
from the conditioned culture medium of human 
fibroblasts, also bound to immobilized 36 kDa 
-72K 
wm I 
-36K 
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Fig.4. Two-dimensional electrophoresis of purified ?- 
labeled 36 kDa protein. The positions of the monomer 
and dimer are indicated by one and two asterisks, 
respectively. 
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protein (fig.3B). Since control experiments with 
polyclonal anti-fibronectin antibodies showed that 
they detect immobilized human plasma and 
cellular fibronectins with equal sensitivity, the bin- 
ding curves for plasma and cellular fibronectins 
could be compared. The comparison suggests that 
cellular fibronectin binds better to the 36 kDa 
protein. 
The synthetic peptide GRGDSP did not affect 
the binding of fibronectin to immobilized 36 kDa 
protein. Increasing concentrations of NaCl in- 
hibited the binding, 0.3 M NaCl giving 50% in- 
hibition compared to the standard conditions 
(0.15 M NaCl). The reaction was maximal at pH 
5-6 and was inhibited at pH I 4 or pH > 8. 
Migration of the 36 kDa protein in SDS-PAGE 
under non-reducing and reducing conditions sug- 
gests that it is a monomeric protein partially 
dimerized under non-reducing conditions. When 
stored at 4°C it partly aggregated into a dimeric 
form. The 36 kDa protein is quite stable, no 
degradation products having been observed. The 
protein was regularly stored in the presence of 
DOC; its behaviour in gel chromatography, among 
other observations, indicated that it is relatively in- 
soluble. According to the two-phase separation ex- 
periments it is amphipathic; it was found to be 
separated into both the hydrophilic and 
hydrophobic phases. The isoelectric point (fig.4) 
of monomeric 36 kDa protein is pH 5.9 and that of 
its dimeric form (72 kDa) pH 6.8. 
Here, we describe a novel fibronectin-binding 
36 kDa protein of normal human fibroblasts. 
When fibroblast proteins were separated by SDS- 
PAGE and transferred onto nitrocellulose, 
fibronectin bound to three proteins of 160, 140 and 
36 kDa. Purified 36 kDa protein bound both 
purified plasma and cellular fibronectins. In the 
approach we have taken, using blotting with 
fibronectin, we also detected 160 and 140 kDa pro- 
teins which may be identical to those described by 
others (see above). The antibodies raised 
(anti-36 kDa protein) reacted only with the 36 kDa 
protein and not with the other two. This indicates 
that the 36 kDa protein is a distinct protein and 
not a degradation fragment of the others. 
Why was the 36 kDa fibronectin-binding protein 
not detected previously? One reason could be that 
this protein is quite adhesive. It could not be 
purified by chromatographic methods. Detergent 
was necessary to maintain the protein soluble and 
prevent its binding to insoluble cellular material. A 
second reason is that the protein was detected only 
by native fibronectin. For instance, iodination of 
fibronectin - previously known to modify 
fibronectin’s interactions [26] - could not be used 
in the detection of this fibronectin-binding protein. 
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